A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd).
Phase of Trial: Phase III
Latest Information Update: 29 Aug 2018
At a glance
- Drugs Budesonide (Primary)
- Indications IgA nephropathy
- Focus Registrational; Therapeutic Use
- Acronyms Nefigard
- Sponsors Calliditas Therapeutics
- 14 Apr 2018 Status changed from planning to recruiting.
- 09 Jan 2017 According to a Pharmalink media release, this trial is expected to begin in 2017.
- 26 Nov 2013 New trial record